Skip to content
Study details
Enrolling now

Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies

University of Chicago
NCT IDNCT04361708ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

54

Study length

about 7.1 years

Ages

18+

Locations

1 site in IL

About this study

Researchers are testing the safety of a treatment combining irinotecan with 5-FU, leucovorin/folinic acid, oxaliplatin, and docetaxel. The trial will involve adults who have adenocarcinoma, gastroesophageal junction adenocarcinoma, or pancreatic adenocarcinoma.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take 5-Fluorouracil
  • 2.Take Docetaxel
  • 3.Take Irinotecan
  • +2 more
PhasePhase 1
Drug5-Fluorouracil

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low14%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

fluorouracil (Antimetabolite; mimics uracil to disrupt DNA/RNA in cancer cells), docetaxel, irinotecan, Antidotes, Deterrents, and Toxicologic Agents (Enzyme Interactions), oxaliplatin

Drug routes

infusion, injection (Injection)

Endpoints

Secondary: Overall Response Rate, Overall survival rate, Progression free survival rate